Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction from a Secondary Database Analysis

This study analyzed the real-world use of ritlecitinib, an oral treatment for severe alopecia areata (AA), in 123 adults in the USA. The average patient age was 37 years, with a mean disease duration of 2.1 years. Nearly half of the patients were using ritlecitinib as their first AA treatment. Results showed that hair regrowth and treatment satisfaction increased with longer treatment duration: 49% of patients experienced hair regrowth within 3 months, rising to 82% after more than 6 months. Satisfaction with AA control also improved from 54% to 85% over the same period. Many patients initially felt embarrassed, frustrated, and anxious due to their condition. Ritlecitinib was chosen for its efficacy, safety, and cost-effectiveness, and it was found to improve hair growth and quality of life, particularly with sustained use.